Adaptive Biotechnologies (ADPT) CFO receives 61,875-share stock grant

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp reported that its Chief Financial Officer, Kyle Piskel, acquired 61,875 shares of common stock as a grant or award on March 4, 2026. The shares were recorded at a price of $0.00 per share, indicating they were not purchased on the open market but received as compensation. Following this transaction, Piskel directly owned 278,512 shares of Adaptive Biotechnologies common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider PISKEL KYLE

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	61,875	$0.00	--

Holdings After Transaction: Common Stock — 278,512 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PISKEL KYLE

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		61,875	A	$0	278,512	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kyle Piskel	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Adaptive Biotechnologies (ADPT) report for Kyle Piskel?

Adaptive Biotechnologies reported that Chief Financial Officer Kyle Piskel received a grant of 61,875 shares of common stock. The award was recorded at $0.00 per share, reflecting stock-based compensation rather than an open-market purchase.

Was the ADPT CFO transaction a stock purchase or an equity grant?

The ADPT CFO transaction was an equity grant, not a purchase. Form 4 data classify it as a “grant, award, or other acquisition” of 61,875 common shares at $0.00 per share, typical of stock-based compensation packages.

How many Adaptive Biotechnologies shares does CFO Kyle Piskel own after this Form 4?

After the reported grant, CFO Kyle Piskel directly owns 278,512 shares of Adaptive Biotechnologies common stock. This reflects his updated direct holdings following the 61,875-share award disclosed in the Form 4 insider filing.

What is the transaction code meaning for Kyle Piskel’s Form 4 in ADPT?

The transaction code on Kyle Piskel’s Form 4 is “A,” which signifies a grant, award, or other acquisition. In this case, it represents a 61,875-share equity award of Adaptive Biotechnologies common stock at no cash cost per share.

Did the Adaptive Biotechnologies CFO pay cash for the 61,875 ADPT shares?

The CFO did not pay cash for these shares. The Form 4 lists a transaction price of $0.00 per share for the 61,875 common shares, indicating they were issued as a grant or award, rather than bought in the open market.